Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33

Previous efforts to develop drugs that directly inhibit the activity of mutant KRAS, the most commonly mutated human oncogene, have not been successful. Cancer cells driven by mutant KRAS require expression of the serine/threonine kinase STK33 for their viability and proliferation, identifying STK33...

詳細記述

保存先:
書誌詳細
主要な著者: Azoitei, Ninel, Hoffmann, Christopher M., Ellegast, Jana M., Ball, Claudia R., Obermayer, Kerstin, Gößele, Ulrike, Koch, Britta, Faber, Katrin, Genze, Felicitas, Schrader, Mark, Kestler, Hans A., Döhner, Hartmut, Chiosis, Gabriela, Glimm, Hanno, Fröhling, Stefan, Scholl, Claudia
フォーマット: Artigo
言語:Inglês
出版事項: The Rockefeller University Press 2012
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3328372/
https://ncbi.nlm.nih.gov/pubmed/22451720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20111910
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料